Webb Emma A, Balasubramanian Meena, Fratzl-Zelman Nadja, Cabral Wayne A, Titheradge Hannah, Alsaedi Atif, Saraff Vrinda, Vogt Julie, Cole Trevor, Stewart Susan, Crabtree Nicola J, Sargent Brandi M, Gamsjaeger Sonja, Paschalis Eleftherios P, Roschger Paul, Klaushofer Klaus, Shaw Nick J, Marini Joan C, Högler Wolfgang
Department of Endocrinology and Diabetes, Birmingham Children's Hospital, Birmingham B4 6NH, United Kingdom.
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, United Kingdom.
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2019-2028. doi: 10.1210/jc.2016-3766.
Recessive mutations in TMEM38B cause type XIV osteogenesis imperfecta (OI) by dysregulating intracellular calcium flux.
Clinical and bone material phenotype description and osteoblast differentiation studies.
Natural history study in pediatric research centers.
Eight patients with type XIV OI.
Clinical examinations included bone mineral density, radiographs, echocardiography, and muscle biopsy. Bone biopsy samples (n = 3) were analyzed using histomorphometry, quantitative backscattered electron microscopy, and Raman microspectroscopy. Cellular differentiation studies were performed on proband and control osteoblasts and normal murine osteoclasts.
Type XIV OI clinical phenotype ranges from asymptomatic to severe. Previously unreported features include vertebral fractures, periosteal cloaking, coxa vara, and extraskeletal features (muscular hypotonia, cardiac abnormalities). Proband lumbar spine bone density z score was reduced [median -3.3 (range -4.77 to +0.1; n = 7)] and increased by +1.7 (1.17 to 3.0; n = 3) following bisphosphonate therapy. TMEM38B mutant bone has reduced trabecular bone volume, osteoblast, and particularly osteoclast numbers, with >80% reduction in bone resorption. Bone matrix mineralization is normal and nanoporosity low. We demonstrate a complex osteoblast differentiation defect with decreased expression of early markers and increased expression of late and mineralization-related markers. Predominance of trimeric intracellular cation channel type B over type A expression in murine osteoclasts supports an intrinsic osteoclast defect underlying low bone turnover.
OI type XIV has a bone histology, matrix mineralization, and osteoblast differentiation pattern that is distinct from OI with collagen defects. Probands are responsive to bisphosphonates and some show muscular and cardiovascular features possibly related to intracellular calcium flux abnormalities.
跨膜蛋白38B(TMEM38B)中的隐性突变通过调节细胞内钙通量失调导致XIV型成骨不全(OI)。
临床和骨材料表型描述以及成骨细胞分化研究。
儿科研究中心的自然史研究。
8例XIV型OI患者。
临床检查包括骨密度、X线片、超声心动图和肌肉活检。使用组织形态计量学、定量背散射电子显微镜和拉曼显微光谱分析骨活检样本(n = 3)。对先证者和对照成骨细胞以及正常小鼠破骨细胞进行细胞分化研究。
XIV型OI临床表型从无症状到严重不等。以前未报告的特征包括椎体骨折、骨膜覆盖、髋内翻和骨骼外特征(肌肉张力减退、心脏异常)。先证者腰椎骨密度z评分降低[中位数-3.3(范围-4.77至+0.1;n = 7)],双膦酸盐治疗后增加了+1.7(1.17至3.0;n = 3)。TMEM38B突变骨的小梁骨体积、成骨细胞,特别是破骨细胞数量减少,骨吸收减少>80%。骨基质矿化正常,纳米孔隙率低。我们证明了一种复杂的成骨细胞分化缺陷,早期标志物表达降低,晚期和矿化相关标志物表达增加。小鼠破骨细胞中三聚体细胞内阳离子通道B型比A型表达占优势,支持低骨转换潜在的内在破骨细胞缺陷。
XIV型OI具有与胶原缺陷型OI不同的骨组织学、基质矿化和成骨细胞分化模式。先证者对双膦酸盐有反应,一些患者表现出可能与细胞内钙通量异常相关的肌肉和心血管特征。